CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
工程化表达嵌合抗原受体（CAR）或修饰T细胞受体（TCR）等转基因的T细胞代表了癌症治疗的新支柱。使用CRISPR/Cas基因编辑工具现在能够对工程化T细胞疗法的命运和功能进行更强、更精确的控制，包括多重基因组编辑以促进使用现成的异体T细胞，以及有可能克服经典Cas9介导DNA切割某些局限性的新方法。本综述总结了已在临床前研究中使用的CRISPR/Cas技术，并概述了目前正在临床试验中测试的技术。
T cells engineered to express transgenes such as chimeric antigen receptors (CAR) or modified T cell receptors (TCR) represent a new pillar of cancer therapy. Use of CRISPR/Cas gene-editing tools now allows even stronger and more precise control over the fate and function of engineered T cell therapies, including multiplex genome editing to facilitate use of off-the-shelf allogeneic T cells and novel approaches which have the potential to overcome some of the limitations of canonical Cas9-mediated DNA cleavage.
This review summarizes the CRISPR/Cas techniques that have been used in preclinical research and outlines those that currently being tested in clinical trials.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
